NCT02689336 2019-09-09
Erlotinib in Combination With Temozolomide in Treating Relapsed/Recurrent/Refractory Pediatric Solid Tumors
Washington University School of Medicine
Phase 2 Withdrawn
Washington University School of Medicine
University of Texas Southwestern Medical Center
Children's Oncology Group
Penn State University
Eli Lilly and Company